WOFIE stimulates regulatory T cells: A 2-year follow-up of renal transplant recipients

Transplantation

Volumn 81, Issue 11, 2006, Pages 1549-1557

  Dresske, Bettina ^a   Haendschke, Frank ^a   Lenz, Philine ^a   Ungefroren, Hendrik ^a   Jenisch, Stefan ^a   Exner, Beate ^a   Mokhtari, Nour Eddine El ^a   Lu, Tim ^a   Zavazava, Nicholas ^b   Faendrich, Fred ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Operational tolerance; Regulatory T cells; Renal transplantation; Steroid withdrawal; WOFIE

Indexed keywords

DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ACNE; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASEPTIC NECROSIS; CATARACT; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MALE; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE;

ADOLESCENT; ADULT; ANTIGENS, CD4; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION TOLERANCE;

EID: 33745155807     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000210538.93861.ae     Document Type: Article

References (46)

1. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605.
2. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735.
3. Wheeler DC, Steiger J. Evolution and etiology of cardiovascular diseases in renal transplant recipients. Transplantation 2000; 70: SS41.
4. Silkensen JR. Long-term complications in renal transplantation. J Am Soc Nephrol 2000; 11: 582.
5. Fellström B. Risk factors for and management of post-transplantation cardiovascular disease. Biodrugs 2001; 15: 261.
6. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580.
7. Hricik DE. Steroid-free immunosuppression in kidney transplantation: an editorial review. Am J Transplant 2002; 2: 19.
8. Calne RY, Watson CJ, Brons IG, et al. Tolerance of porcine renal allografts induced by donor spleen cells and seven days' treatment with cyclosporine. Transplantation 1994; 57: 1433.
9. Calne R, Moffatt SD, Friend PJ, et al. Campath1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68: 1613.
10. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (Campath 1H) induction therapy in cadaveric kidney transplantation: efficacy and safety at five years. Am J Transplant 2005; 5: 1437.
11. Dresske B, Zavazava N, Huang DS, Lin X, Kremer B, Fandrich F. WOFIE augments the immunosuppressive potency of FK-506. Transplant Immunol 1998; 6: 243.
12. Dresske B, Zavazava N, Jenisch S, et al. WOFIE synergizes with calcineurin-inhibitor treatment and early steroid withdrawal in kidney transplantation. Transplantation 2003; 75: 1286.
13. Taylor PA, Noelle RJ, Blazar BR. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance against alloantigen via costimulatory blockade. J Exp Med 2001; 193: 1311.
14. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
15. Chen WB, Lenschow W, Tiede K, Fischer JW, Kalthoff H, Ungefroren H. Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-β in pancreatic tumor cells. J Biol Chem 2002; 277: 36118.
16. Lo A, Alloway RR. Strategies to reduce toxicities and improve outcomes in renal transplant recipients. Pharmacotherapy 2002; 22: 316.
17. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910.
18. Pascual J, Quereda C, Zamora J, Hernanadez D. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation 2004; 78: 1548.
19. Birkeland SA. Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients. Transplantation 2001; 71: 1089.
20. Kandaswamy R, Melancon JK, Dunn T, et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients-an interim analysis. Am J Transplant 2005; 5: 1529.
21. Rostaing L, Cantarovich D, Mourad G, et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005; 79: 807.
22. Ehrlich HA, Opelz G, Hansen J. HLA DNA typing and transplantation. Immunity 2001; 14: 347.
23. Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 1984; 312: 548.
24. Chavin KD, Qin L, Lin J, Yagita H, Bromberg JS. Combined anti-CD2 and anti-CD3 receptor monoclonal antibodies induce donor-specific tolerance in a cardiac transplant model. J Immunol 1993; 151: 7249.
25. Parker DC, Greiner DL, Phillips NE, et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA 1995; 92: 9560.
26. + suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2: 389.
27. + regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J Immunol 2004; 172: 6003.
28. Itoh M, Takahashi T, Sakaguchi N, et al. Thymus and autoimmunity: production of CD4+CD25+ naturally anergic and suppressive T cells as key function of the thymus in maintaining immunologic self-tolerance. J Immunol 1999; 162: 5317.
29. +high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245.
30. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193: 1285.
31. Ng WF, Duggan PJ, Ponchel F, et al. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood 2001; 98: 2736.
32. Stephens LA, Mottet C, Mason D, Powrie F. Human CD4(+)CD25(+) thymocytes and peripheral T cells have immunosuppressive activity in vitro. Eur J Immunol 2001; 31: 1247.
33. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000; 101: 455.
34. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151.
35. + regulatory T cells. Int Immunol 2004; 16: 1189.
36. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057.
37. + regulatory T cells. Nat Immunol 2003; 4: 330.
38. Hara M, Kingsley CI, Niimi M, et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001; 166: 3789.
39. Yamada A, Chandraker A, Laufer TM, Gerth AJ, Sayegh MH, Auchincloss H. Recipient MHC class II expression is required to achieve long-term survival of murine cardiac allografts after costimulatory blockade. J Immunol 2001; 167: 5522.
40. Womer KL, Stone JR, Murphy B, Chandraker A, Sayegh MH. Indirect allorecognition of donor class I and II major histocompatibility complex peptides promotes the development of transplant vasculopathy. J Am Soc Nephrol 2001; 12: 2500.
41. Lee RS, Yamada K, Houser SL, et al. Indirect recognition of allopeptides promotes the development of cardiac allograff vasculopathy. Proc Natl Acad Sci U S A 2001; 98: 3276.
42. + T cells in human kidney transplant recipients. J Am Soc Nephrol 2003; 14: 1643.
43. Li Y, Koshiba T, Yoshizawa A, et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 2004; 4: 2118.
44. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004; 77: 166.
45. Furtado GC, Olivares-Villagomez D, Curotto de Lafaille MA, Kutchukhidze N, Lafaille JJ. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp Med 2002; 196: 851.
46. Takatsuki M, Uemoto S, Inomata Y, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001; 72: 449.